CTOs on the Move

Xeris Pharmaceuticals

www.xerispharma.com

 
It`s all about the experience. Everything we do is about simplifying and making things better and easier. It`s about making a difference in people`s lives.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.xerispharma.com
  • 180 North LaSalle Street Suite 1600
    Chicago, IL USA 60601
  • Phone: 844.445.5704

Executives

Name Title Contact Details
Curtis R
Manager of IT Infrastructure and Security Profile

Funding

Xeris Pharmaceuticals raised $41M on 01/07/2016
Xeris Pharmaceuticals raised $10M on 03/08/2018
Xeris Pharmaceuticals raised $45M on 03/08/2018
Xeris Pharmaceuticals raised $27M on 03/11/2021
Xeris Pharmaceuticals raised $30M on 01/03/2022

Similar Companies

Bell Pharmaceuticals

Bell Pharmaceuticals is a Belle Plaine, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taisho Pharmaceutical California

Taisho Pharmaceutical California is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OrthoArizona

Enjoy the freedom of a pain-free, active lifestyle with help from our orthopedic specialists at OrthoArizona. Learn more today!

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.